scholarly journals Anti-mitotic therapies in cancer

2018 ◽  
Vol 218 (1) ◽  
pp. 10-11 ◽  
Author(s):  
Julia Tischer ◽  
Fanni Gergely
Keyword(s):  
Cancer Patients ◽  
Cell Biology ◽  
Clinical Use ◽  
Microtubule Poisons

Tischer and Gergely review the cell biology behind microtubule poisons and their clinical use in cancer patients.

Interleukin-11: Review of Molecular, Cell Biology, and Clinical Use

Blood ◽  
1997 ◽  
Vol 89 (11) ◽  
pp. 3897-3908 ◽  
Author(s):  
Xunxiang Du ◽  
David A. Williams
Keyword(s):  
Cell Biology ◽  
Clinical Use ◽  
Molecular Cell Biology ◽  
Interleukin 11

scholarly journals Ketamine Inhibits Ovarian Cancer Cell Growth by Regulating the lncRNA-PVT1/EZH2/p57 Axis

2021 ◽  
Vol 11 ◽  
Author(s):  
Tao Li ◽  
Jie Yang ◽  
Ben Yang ◽  
Guoqing Zhao ◽  
Hai Lin ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Cancer Cell ◽  
Cell Biology ◽  
Ovarian Cancer Cell ◽  
Pain Treatment ◽  
Ovarian Cancer Cells ◽  
Cancer Cell Growth ◽  
Ovarian Cancer Cell Lines ◽  
Rna Immunoprecipitation

Ketamine is widely used for cancer pain treatment in clinic, and has been shown to inhibit various tumor cells growth. However, the effect of ketamine on ovarian cancer cells growth and the downstream molecules has not been defined. In the present study, we found that ketamine significantly inhibited the proliferation and survival of six ovarian cancer cell lines. Moreover, ketamine induced ovarian cancer cell cycle arrest, apoptosis, and inhibited colony formation capacity. Since lncRNAs have been identified as key regulators of cancer development, we performed bioinformatics analysis of a GEO dataset and found fourteen significantly altered lncRNAs in ovarian cancer patients. We then investigated the effect of ketamine on these lncRNAs, and found that ketamine regulated the expression of lncRNA PVT1. Mechanistically, ketamine regulated P300-mediated H3K27 acetylation activation in the promoter of PVT1. Our RNA immunoprecipitation experiment indicated that PVT1 bound histone methyltransferase enhancer of zeste homolog 2 (EZH2), and regulated the expression of target gene, including p57, and consequently altered ovarian cancer cell biology. Our study revealed that ketamine could be a potential therapeutic strategy for ovarian cancer patients.

PD-0357: Clinical use of iterative 4D CBCT reconstructions to investigate tumor motion of lung cancer patients

2014 ◽  
Vol 111 ◽  
pp. S137-S138
Author(s):  
M.L. Schmidt ◽  
T.S. Sørensen ◽  
D.C. Hansen ◽  
L. Hoffmann ◽  
J. Toftegaard ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Clinical Use ◽  
Tumor Motion ◽  
Lung Cancer Patients

Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

2011 ◽  
Vol 28 (1) ◽  
pp. 57-67 ◽  
Author(s):  
Aurelia Bustos ◽  
Ruth Álvarez ◽  
Pedro Miguel Aramburo ◽  
Francisco Carabantes ◽  
Nieves Díaz ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Darbepoetin Alfa ◽  
Clinical Use

scholarly journals Donald Metcalf AC. 26 February 1929 — 15 December 2014

2016 ◽  
Vol 62 ◽  
pp. 409-431
Author(s):  
Nicos A. Nicola
Keyword(s):  
Growth Factors ◽  
Progenitor Cells ◽  
Human Health ◽  
Cancer Patients ◽  
Mechanisms Of Action ◽  
Clinical Use ◽  
Medical Researchers

Donald Metcalf was one of Australia's most distinguished medical researchers and is acknowledged internationally as the father of the modern field of haemopoietic growth factors. He defined the hierarchy of haemopoietic progenitor cells, purified and cloned the major molecular regulators of their growth and maturation, determined their mechanisms of action and participated in their development for clinical use in cancer patients. He received numerous awards and distinctions during his career, but was most pleased by the fact that his life's work improved human health.

Sign in / Sign up

Export Citation Format

Share Document